SRSF1 and Miyoshi myopathy: Furthermore, a significantly higher SRSF1 expression was observed in ISS stage III when compared with stage I or II (p = 0.011, Kruskal–Wallis test, Figure 3(b)), which specifically occurs in IgG-type MM (p = 0.013 and 0.01, respectively, Kruskal–Wallis test, Figure 3(c)), but not in free light chain (FLC)- or IgA-type MM (p = 0.878 and 0.123, respectively, Figure 3(c)).